1. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. (9th January 2018) Authors: Guibert, N; Hu, Y; Feeney, N; Kuang, Y; Plagnol, V; Jones, G; Howarth, K; Beeler, J F; Paweletz, C P; Oxnard, G R Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 1049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. (22nd February 2019) Authors: Blumenthal, G M; Gong, Y; Kehl, K; Mishra-Kalyani, P; Goldberg, K B; Khozin, S; Kluetz, P G; Oxnard, G R; Pazdur, R Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (20th March 2019) Authors: Li, B T; Janku, F; Jung, B; Hou, C; Madwani, K; Alden, R; Razavi, P; Reis-Filho, J S; Shen, R; Isbell, J M; Blocker, A W; Eattock, N; Gnerre, S; Satya, R V; Xu, H; Zhao, C; Hall, M P; Hu, Y; Sehnert, A J; Brown, D Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 597 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗